UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2001-09, Vol.345 (12), p.861-869

2001

Link zum Volltext

Verfügbarkeit prüfen

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The American statistician, 2005-11, Vol.59 (4), p.301-307

2005

Link zum Volltext

Verfügbarkeit prüfen

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Kidney international, 2003-04, Vol.63 (4), p.1499-1507

2003

Link zum Volltext

Verfügbarkeit prüfen

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2004-07, Vol.292 (1), p.55

2004

Link zum Volltext

Verfügbarkeit prüfen

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Diabetes care, 2006-03, Vol.29 (3), p.595-600

2006

Link zum Volltext

Verfügbarkeit prüfen

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Link zum Volltext

Verfügbarkeit prüfen

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

The American journal of cardiology, 2005-12, Vol.96 (11), p.1530-1536

2005

Link zum Volltext

Verfügbarkeit prüfen

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS Trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)

Circulation (New York, N.Y.), 1999-10, Vol.100 (15), p.1609-1615

1999

Link zum Volltext

Verfügbarkeit prüfen

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Circulation (New York, N.Y.), 2006-03, Vol.113 (12), p.1588-1596

2006

Link zum Volltext

Verfügbarkeit prüfen

Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients

Hypertension (Dallas, Tex. 1979), 2004-07, Vol.44 (1), p.48-54

2004

Link zum Volltext

Verfügbarkeit prüfen

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Link zum Volltext

Verfügbarkeit prüfen

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Circulation (New York, N.Y.), 2002-05, Vol.105 (20), p.2361-2366

2002

Link zum Volltext

Verfügbarkeit prüfen

Proportion of treatment effect (PTE) explained by a surrogate marker

Statistics in medicine, 2003-11, Vol.22 (22), p.3449-3459

2003

Link zum Volltext

Verfügbarkeit prüfen

Sex-based short- and long-term survival in patients following complicated myocardial infarction

European heart journal, 2006-09, Vol.27 (18), p.2177-2183

2006

Link zum Volltext

Verfügbarkeit prüfen

Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

The American heart journal, 2005-05, Vol.149 (5), p.846-850

2005

Link zum Volltext

Verfügbarkeit prüfen

Importance of baseline distribution of proteinuria in renal outcomes trials : Lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Journal of the American Society of Nephrology, 2005-06, Vol.16 (6), p.1775-1780

2005

Link zum Volltext

Verfügbarkeit prüfen

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension (Dallas, Tex. 1979), 2005-04, Vol.45 (4), p.580-585

2005

Link zum Volltext

Verfügbarkeit prüfen

Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: Insights from the PRISM-PLUS study

International journal of cardiology, 2005-04, Vol.100 (1), p.73-78

2005

Link zum Volltext

Verfügbarkeit prüfen

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension : the RENAAL and LIFE studies

Journal of hypertension, 2007-04, Vol.25 (4), p.871-876

2007

Link zum Volltext

Verfügbarkeit prüfen

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (19), p.2343

2004

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.1004-1010

2002

Link zum Volltext

Verfügbarkeit prüfen

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

JAMA : the journal of the American Medical Association, 2002-09, Vol.288 (12), p.1491

2002

Link zum Volltext

Verfügbarkeit prüfen

An analysis of cholesterol control and statin use in the losartan intervention for endpoint reduction in hypertension study

Clinical therapeutics, 2003-04, Vol.25 (4), p.1186-1199

2003

Link zum Volltext

Verfügbarkeit prüfen

Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction

International journal of cardiology, 2009-04, Vol.133 (2), p.229-232

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(37)
Humans
(32)
Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Male
(29)
Aged
(28)
Female
(28)
Middle Aged
(27)
Cardiology. Vascular System
(18)
Pharmacology. Drug Treatments
(18)
Cardiovascular System & Cardiology
(17)
Losartan - Therapeutic Use
(16)
Heart
(15)
Hypertension - Drug Therapy
(14)
Medicin Och Hälsovetenskap
(14)
Antihypertensive Agents - Therapeutic Use
(13)
Atenolol - Therapeutic Use
(13)
Double-Blind Method
(13)
Cardiac & Cardiovascular Systems
(12)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Proportion of treatment effect (PTE) explained by a surrogate marker

Sex-based short- and long-term survival in patients following complicated myocardial infarction

Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Importance of baseline distribution of proteinuria in renal outcomes trials : Lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: Insights from the PRISM-PLUS study

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension : the RENAAL and LIFE studies

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

An analysis of cholesterol control and statin use in the losartan intervention for endpoint reduction in hypertension study

Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction

Aktive Filter

Suchergebnisse filtern